MTOR and cancer: A pan-cancer proteogenomic survey of the PI3K/AKT/mTOR pathway conducted on 11,219 tissue samples has shown that nearly one-fifth of tumors have high mTOR pathway activation that cannot be explained by the presence of underlying genomic alterations of the PIK3CA signaling axis [62].